Chamber and committees

The opening of a Scottish Government office in Warsaw is currently under review given ongoing budget pressures.

The Scottish Government is committed to improving life expectancy and tackling health inequalities across Scotland. The recently published Population Health Framework, a joint publication by the Scottish Government and COSLA, highlights that the circumstances and environments in which people are born, grow up, live, work and age – known as the building blocks of health – are the most influential factors shaping health outcomes.

The Framework’s supporting evidence paper notes that Scotland has experienced a decline in healthy life expectancy – the number of years people can expect to live in good health – alongside a stalling of improvements in mortality rates after decades of steady progress. These trends are associated with several major factors: the UK Government’s austerity policies during the 2010s, Brexit, the COVID-19 pandemic, and the ongoing cost-of-living crisis. Together, these influences have weakened the building blocks of health, widened existing inequalities, and exacerbated Scotland’s longstanding disparities in income, wealth, and power.

In response, the Population Health Framework sets out a whole-system cross-government and cross-sector approach centred on prevention. This approach builds on existing Scottish Government actions, including initiatives on diet and healthy weight, and efforts to tackle child poverty. Through this approach, the Scottish Government aims to raise overall life expectancy while closing the gap between the most deprived 20% of communities and the national average by 2035.

I refer the member to the answer to question S6W-37406 on 19 May 2025. All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers.

The Scottish Government has a strong track record in the investment in and delivery of affordable homes. Since 2007 we have supported the delivery of more than 139,000 affordable homes, with 99,000 of these being made available for social rent. This has resulted in the delivery of affordable homes in Scotland being 47% more per head of population than in England, and 73% more than in Wales. However, prevailing economic conditions across the United Kingdom in recent years, driven by EU-exit, Covid-19 and wider global pressures, has made delivery in recent years more challenging. For example, construction inflation reached 24% in the summer of 2022.

Despite these headwinds we remain absolutely committed to our longstanding affordable home ambitions. We are investing £808 million in 2025-26 alone, and remain focused on delivering at least 70% of homes for social rent towards our 110,000 affordable homes target. This investment includes a doubling of our acquisition fund from £40 million to £80 million in 2025-26 helping to deliver homes more quickly, the majority of which will be for social rent. Of the 28,537 affordable homes delivered to end March 2025 against our target, 77% are for social rent.

We have announced plans to invest up to £4.9 billion over the next four years in a multi-annual, multi-billion pound affordable housebuilding project and continue to work with partners to maximise delivery in Scotland.

The number of Newly Qualified Paramedics (NQPs) who have joined the Scottish Ambulance Service in the North Region since 2023 are as follows:

2023-24 - 35

2024-25 - 48

2025-26 to date - 36

The National Child Sexual Abuse and Exploitation (CSAE) Strategic Group held an extraordinary meeting on 15 July to consider the Casey Audit. The minutes of the Group’s meetings are published on the Scottish Government website: https://www.gov.scot/groups/national-child-sexual-abuse-and-exploitation-strategic-group/.

It was noted that Police Scotland is undertaking a number of activities in relation to the Casey Audit including an initial assessment of the current child sexual abuse investigative landscape across Scotland, an analytical review looking at previous group based offending investigations and are carrying out a mapping of CSAE policy, process, practice and investigations. An update on this work will be provided at the Group’s next meeting in October at which there will be further discussion of the Audit findings, alongside other key inquiries and practice reviews including the Independent Inquiry into Child Abuse (IICSA) to inform next steps in its ambition to enhance our shared response to child sexual abuse and exploitation in Scotland.

Scotland’s National Child Protection Data Group also discussed the Audit’s data findings and recommendations in July and officials are taking forward work to explore opportunities to improve data and intelligence on this issue.

Scottish Government officials continue to engage with the UK Government’s response to the Casey Audit to understand implications for Scotland and opportunities to work together and share learning.

I refer the member to the answer to question S6W-37406 on 19 May 2025. All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers.

There are studies that show a developing evidence base for the use of mifepristone in breast cancer prevention as outlined in the opinion piece in The Lancet.

The regulation for the licensing, safety and efficacy of medicines is currently reserved to the UK Government and is the responsibility of the Medicines and Healthcare products Regulatory Agency (MHRA). The MHRA is also responsible for enabling innovation, research and development that is beneficial to public health, including overseeing clinical trials which underpin evidence based practice. Clinical trials are an important part of the pathway by which a new medicinal product or a new use of an existing medicine can be marketed for use as a new treatment.

Before a medicine can be marketed, a pharmaceutical company must be able to demonstrate its safety, quality and efficacy. A marketing authorisation (sometimes called a licence) is granted to market a medicine for a specific indication (condition) and not to the medicine itself. The decision to apply for a marketing authorisation for a new medicine or new indication is for a pharmaceutical company to make. In doing so they must include data from clinical trials and other studies demonstrating the quality, safety and efficacy of the medicine. After detailed assessment and providing the data is satisfactory, a marketing authorisation may be granted.

Any preparations in relation to the proposals for the opening of a Scottish Government office in Warsaw have been undertaken by officials with the Directorate for Culture and External Affairs as part of normal business.

The Scottish Government supports the culture sector to make its own decisions relating to artistic or cultural judgement. How individual cultural organisations engage in public debate is a matter for them, as are their programming decisions. Artists and cultural organisations are free to explore and convene dialogue on any issues whilst having regard to relevant legislation, such as the Equality Act.